Platelets to surrogate lung inflammation in COVID-19 patients

Haripriya Kuchi Bhotla, Tanushri Kaul, Balamuralikrishnan Balasubramanian, Murugesh Easwaran, Vijaya Anand Arumugam, Manikantan Pappusamy, Saravanan Muthupandian, Arun Meyyazhagan

Research output: Contribution to journalLetterpeer-review

6 Scopus citations


The neoteric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been jeopardizing the world with the symptoms of seasonal flu. The virus contagion predicted to have been originated from Wuhan, China has by far trapped 4,198,418 cases from 212 countries in the world with two international conveyances with 284,102 deaths as of 11 May 2020 (10:18 GMT). Researchers around the globe have indulged in deciphering viral mode in the body for devising a cure. Affirmations from autopsies and preliminary findings on SARS-CoV-2 hypothesized on viral pathogenesis within the host, for instance, source of inflammation in lungs and pneumonia. This hypothesis assigns the platelets as agents of infection after viral entry. Presently, curbing infection to stall the spread of SARS-CoV-2 is the prima facie intervention employed, worldwide. However, public health authorities must monitor the state of affairs scrupulously, as the deeper our understanding of this novel virus and its associated outbreak, the better we can deal with it. Knowing this idea might be far-fetched, yet this postulate would serve as the groundwork for the present situation.

Original languageEnglish
Article number110098
JournalMedical Hypotheses
StatePublished - Oct 2020


  • COVID-19
  • Lung inflammation
  • Pathogenesis
  • Platelets
  • Thrombocytopenia


Dive into the research topics of 'Platelets to surrogate lung inflammation in COVID-19 patients'. Together they form a unique fingerprint.

Cite this